Article info

Download PDFPDF
Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study
  1. Correspondence to Professor George V Papatheodoridis, 2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, 114 Vas. Sophias ave., 115 27 Athens, Greece; gepapath{at}med.uoa.gr
View Full Text

Citation

Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al
Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study

Publication history

  • Revised December 10, 2010
  • Accepted December 19, 2010
  • First published January 26, 2011.
Online issue publication 
July 01, 2011

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.